Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Crawford Open To Discussing Independent Drug Safety Office

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."

You may also be interested in...



Drug Safety Legislation To Be Introduced April 27

Sens. Grassley and Dodd are proposing the creation of a “Center for Post-market Drug Evaluation & Research” that would be independent from FDA’s existing drug safety infrastructure. Proposals for an independent drug safety office have elicited mixed reactions from the agency.

Drug Safety Legislation To Be Introduced April 27

Sens. Grassley and Dodd are proposing the creation of a “Center for Post-market Drug Evaluation & Research” that would be independent from FDA’s existing drug safety infrastructure. Proposals for an independent drug safety office have elicited mixed reactions from the agency.

Office Of New Drugs' Oversight Creates Advisory Committee Bias – FDA’s Graham

OND’s role in appointing advisory committee members and deciding what issues receive attention leads to a “pro-drug bias and regulatory conflicts of interest,” Office of Drug Safety’s Graham says. FDA “whistleblower” also criticizes disclosure policies for advisory committee members.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel